Differential Impact of Insulin Sensitizers vs. Anti-Androgen on Serum Leptin Levels in Vitamin D Replete PCOS Women: A Six Month Open Labeled Randomized Study

Abstract

Women with PCOS are linked to insulin resistance, inflammation, and vitamin D (VD) deficiency. The study endeavors to comprehend the differential impact of insulin sensitizers vs. anti-androgen on serum leptin levels among women with PCOS rendered vitamin D replete with high VD oral supplement. This was open-labeled randomized study that screened 180 eligible women presenting to Endocrine clinic with oligomenorrhea or features of hyperandrogenism. Ninety-nine women who furnished written informed consent and fulfilled the Rotterdam 2003 criteria for diagnosis of PCOS were randomized into 3 drug treatment arms to receive either spironolactone (50 mg/d; n=30), metformin (1000 mg/d; n=30) or pioglitazone (30 mg/d; n=30). These women were also administered oral VD (4000 IU/day) in addition to the allocated drug for a period of 6 months. Detailed history, clinical examination, and laboratory evaluation was carried out at baseline and 6 months after intervention. Number of menstrual cycles/year increased while as Ferriman–Gallwey score, blood glucose, HOMA-IR, and plasma insulin levels significantly decreased in all the three arms with better outcomes in spironolactone and pioglitazone arms (p<0.05). Similarly, serum leptin levels superiorly improved in spironolactone and pioglitazone group. Pioglitazone group showed better efficacy in lowering serum total testosterone (p<0.05). Co-supplementation of high dosage VD with spironolactone or pioglitazone are more effective in reducing plasma leptin levels than metformin, and thus might prove to be better therapeutic strategies for women with PCOS.

Key words

polycystic ovary syndrome - hyperandrogenism - insulin resistance - inflammation serum leptin

• References

• 1 Carmina E, Lobo RA. Polycystic Ovary Syndrome (PCOS): Arguably the most common endocrinopathy is associated with significant morbidity in women. J Clin Endocrinol Metab 1999; 84: 1897-1899
• 2 Dumesic DA, Akopians AL, Madrigal VK. et al. Hyperandrogenism accompanies increased intra-abdominal fat storage in normal weight polycystic ovary syndrome women. J Clin Endocrinol Metab 2016; 101: 4178-4188
• 3 Dunaif A. Hyperandrogenic anovulation (PCOS): a unique disorder of insulin action associated with an increased risk of non-insulin-dependent diabetes mellitus. Am J Med 1995; 98: 33S-39S
• 4 Ollila M-ME, West S, Keinänen-Kiukaanniemi S. et al. Overweight and obese but not normal weight women with PCOS are at increased risk of Type 2 diabetes mellitus—a prospective, population-based cohort study. Hum Reprod 2017; 32: 423-431
• 5 Lin T-C, Yen J-M, Gong K-B. et al. Abnormal glucose tolerance and insulin resistance in polycystic ovary syndrome amongst the Taiwanese population- not correlated with insulin receptor substrate-1 Gly972Arg/Ala513Pro polymorphism. BMC Med Genet 2006; 7: 36
• 6 Macut D, Tziomalos K, Božić-Antić I. et al. Non-alcoholic fatty liver disease is associated with insulin resistance and lipid accumulation product in women with polycystic ovary syndrome. Hum Reprod 2016; 31: 1347-1353
• 7 Nehir Aytan A, Bastu E, Demiral I. et al. Relationship between hyperandrogenism, obesity, inflammation and polycystic ovary syndrome. Gynecol Endocrinol 2016; 32: 709-713
• 8 Peng Z, Sun Y, Lv X. et al. Interleukin-6 levels in women with polycystic ovary syndrome: a systematic review and meta-analysis. PLoS One 2016; 11: e0148531
• 9 Sathyapalan T, Javed Z, Kilpatrick ES. et al. Endocannabinoid receptor blockade increases vascular endothelial growth factor and inflammatory markers in obese women with polycystic ovary syndrome. Clin Endocrinol (Oxf) 2017; 86: 384-387
• 10 Adams J, Liu Z, Ren YA. et al. Enhanced inflammatory transcriptome in the granulosa cells of women with polycystic ovarian syndrome. J Clin Endocrinol Metab 2016; 101: 3459-3468
• 11 Koleva DI, Orbetzova MM, Nikolova JG. et al. Adipokines and soluble cell adhesion molecules in insulin resistant and non-insulin resistant women with polycystic ovary syndrome. Arch Physiol Biochem 2016; 122: 223-227
• 12 Zheng S-H, Li X-L. Visceral adiposity index as a predictor of clinical severity and therapeutic outcome of PCOS. Gynecol Endocrinol 2016; 32: 177-183
• 13 Yannakoulia M, Yiannakouris N, Blüher S. et al. Body fat mass and macronutrient intake in relation to circulating soluble leptin receptor, free leptin index, adiponectin, and resistin concentrations in healthy humans. J Clin Endocrinol Metab 2003; 88: 1730-1736
• 14 Glintborg D, Andersen M, Hagen C. et al. Evaluation of metabolic risk markers in polycystic ovary syndrome (PCOS). Adiponectin, ghrelin, leptin and body composition in hirsute PCOS patients and controls. Eur J Endocrinol 2006; 155: 337-345
• 15 Joham AE, Teede HJ, Cassar S. et al. Vitamin D in polycystic ovary syndrome: Relationship to obesity and insulin resistance. Mol Nutr Food Res 2016; 60: 110-118
• 16 Mishra S, Das AK, Das S. Hypovitaminosis D and Associated Cardiometabolic Risk in Women with PCOS. J Clin Diagonstic Res 2016; 10: BC01-4
• 17 Dinca M, Serban M-C, Sahebkar A. et al. Does vitamin D supplementation alter plasma adipokines concentrations? A systematic review and meta-analysis of randomized controlled trials. Pharmacol Res 2016; 107: 360-371
• 18 Figurová J, Dravecká I, Petríková J. et al. The effect of alfacalcidiol and metformin on metabolic disturbances in women with polycystic ovary syndrome. Horm Mol Biol Clin Investig 2017; 29: 85-91
• 19 Tang T, Lord JM, Norman RJ et al. Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility. Cochrane Database Syst Rev. 2012; CD003053
• 20 Ganie MA, Khurana ML, Nisar S. et al. Improved efficacy of low-dose spironolactone and metformin combination than either drug alone in the management of women with Polycystic Ovary Syndrome (PCOS): A six-month, open-label randomized study. J Clin Endocrinol Metab 2013; 98: 3599-3607
• 21 Ashraf Ganie M, Khurana ML, Eunice M. et al. Comparison of efficacy of spironolactone with metformin in the management of polycystic ovary syndrome: An open-labeled study. J Clin Endocrinol Metab 2004; 89: 2756-2762
• 22 Matthews DR, Hosker JP, Rudenski AS. et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412-419
• 23 Geller DH, Pacaud D, Gordon CM. et al. State of the art review: Emerging therapies: The use of insulin sensitizers in the treatment of adolescents with Polycystic Ovary Syndrome (PCOS). Int J Pediatr Endocrinol 2011; 2011: 9
• 24 Kulshreshtha B, Gupta N, Ganie MA. et al. Effect of metformin and spironolactone therapy on OGTT in patients with polycystic ovarian syndrome – a retrospective analysis. Gynecol Endocrinol 2012; 28: 823-826
• 25 Zulian E, Sartorato P, Benedini S. et al. Spironolactone in the treatment of polycystic ovary syndrome: effects on clinical features, insulin sensitivity and lipid profile. J Endocrinol Invest 2005; 28: 49-53
• 26 Bajuk Studen K, Šebeštjen M, Pfeifer M. et al. Influence of spironolactone treatment on endothelial function in non-obese women with polycystic ovary syndrome. Eur J Endocrinol 2011; 164: 389-395
• 27 Messinis IE, Messini CI, Anifandis G. et al. Polycystic ovaries and obesity. Best Pract Res Clin Obstet Gynaecol 2015; 29: 479-488
• 28 Fang F, Ni K, Cai Y. et al. Effect of vitamin D supplementation on polycystic ovary syndrome: A systematic review and meta-analysis of randomized controlled trials. Complement Ther Clin Pract 2017; 26: 53-60
• 29 Tan BK, Chen J, Hu J. et al. Metformin increases the novel adipokine cartonectin/CTRP3 in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2013; 98: E1891-E1900
• 30 Karonova T, Belyaeva O, Jude EB. et al. Serum 25(OH)D and adipokines levels in people with abdominal obesity. J Steroid Biochem Mol Biol 2018; 175: 170-176
• 31 Kim JY, Tfayli H, Michaliszyn SF. et al. Distinguishing characteristics of metabolically healthy versus metabolically unhealthy obese adolescent girls with polycystic ovary syndrome. Fertil Steril 2016; 105: 1603-1611
• 32 Chen C-I, Hsu M-I, Lin S-H. et al. Adiponectin and leptin in overweight/obese and lean women with polycystic ovary syndrome. Gynecol Endocrinol 2015; 31: 264-268
• 33 Cohen B, Novick D, Rubinstein M. Modulation of insulin activities by leptin. Science 1996; 274: 1185-1188
• 34 Jacobs HS, Conway GS. Leptin, polycystic ovaries and polycystic ovary syndrome. Hum Reprod Update 5: 166-171
• 35 Svendsen PF, Christiansen M, Hedley PL. et al. Adipose expression of adipocytokines in women with polycystic ovary syndrome. Fertil Steril 2012; 98: 235-241
• 36 Plati E, Kouskouni E, Malamitsi-Puchner A. et al. Visfatin and leptin levels in women with polycystic ovaries undergoing ovarian stimulation. Fertil Steril 2010; 94: 1451-1456